PPD Named ‘Most Innovative CRO’ by Triangle Business Journal
May 27 2021 - 9:00AM
Business Wire
Honors PPD’s development and implementation of
innovative customer solutions during COVID-19 pandemic
PPD, Inc. (Nasdaq: PPD) has been named “Most Innovative CRO” by
North Carolina’s Triangle Business Journal, recognizing the global
contract research organization’s strong performance in a year
shaped by the COVID-19 pandemic.
PPD’s significant investments to expand capabilities for patient
recruitment for clinical trials, investigator sites, laboratories,
real-world evidence generation and technology solutions positioned
the company, during the pandemic, to successfully provide
continuity for customers’ ongoing trials and to start new trials.
PPD enrolled more than 80,000 patients in COVID-19 trials and
played a key role in helping clients develop COVID-19 vaccines and
therapeutics.
PPD also extended its digital clinical trials solutions to
ensure patients and investigators could continue participating in
trials, with electronic Clinical Outcome Assessments (eCOAs),
remote eConsent, direct to/from patient models, home health care
and nursing, wearables, telemedicine and remote monitoring.
“Recognizing early on that digital and decentralized solutions
would increase trial access for patients and make it easier for
them to participate, we invested in building a team of experts to
design, configure and implement digitally enabled or decentralized
trials,” said Niklas Morton, senior vice president of PPD® Digital.
“Patient safety always has remained at the forefront of our work,
and when the pandemic hit, we were well positioned to respond by
offering an extensive and flexible suite of digital trial solutions
enabling customers to advance their clinical research
programs.”
Based in the Research Triangle region of North Carolina, a nexus
of the CRO industry, the business journal holds its Life Sciences
Awards each year to recognize individuals and research
organizations that are leading the field.
The business journal has also named Brittany Erana, M.P.M., vice
president for PPD Digital, to its 2021 “40 Under 40” list. Erana,
who serves as head of operations for PPD’s digital trials team, has
more than 15 years of experience in global research operations,
strategy, digital implementation and delivery expertise. In her
role, Erana is responsible for designing the operational
infrastructure and capabilities necessary to successfully deliver
decentralized and digitally enabled clinical trials, while
maintaining the same high quality as with traditional clinical
trials.
About PPD
PPD is a leading global contract research organization providing
comprehensive, integrated drug development, laboratory and
lifecycle management services. Our customers include
pharmaceutical, biotechnology, medical device, academic and
government organizations. With offices in 47 countries and more
than 27,000 professionals worldwide, PPD applies innovative
technologies, therapeutic expertise and a firm commitment to
quality to help customers bend the cost and time curve of drug
development and optimize value in delivering life-changing
therapies to improve health. For more information, visit
www.ppd.com.
This news release contains forward-looking statements. These
statements often include words such as “expect,” “believe,”
“project,” “forecast,” “estimate,” “target” and other similar
expressions. Although we believe these forward-looking statements
are based on reasonable assumptions at the time they are made, you
should be aware that many factors could affect our actual financial
results, and therefore actual results might differ materially from
those expressed in the forward-looking statements. Factors that
might materially affect such forward-looking statements include,
but are not limited to, the fragmented and highly competitive
nature of the drug development services industry; changes in trends
in the biopharmaceutical industry; our ability to keep pace with
rapid technological changes that could make our services less
competitive or obsolete; political, economic and/or regulatory
influences and changes; the risks related to the planned
acquisition of PPD by Thermo Fisher Scientific Inc.; and other
factors disclosed under the “Risk Factors” section in our periodic
reports filed with the Securities and Exchange Commission (SEC),
including our latest Annual Report on Form 10-K and Quarterly
Report on form 10-Q, which are available on our website at
https://investors.ppd.com or the SEC’s website at www.sec.gov. We
assume no obligation and disclaim any duty to revise or update any
forward-looking statements, or make any new forward-looking
statement, whether as a result of new information, future events or
otherwise, except as required by applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210527005550/en/
Media: Nadine Maeser +1 919 456 4425 media@ppd.com Investors:
Tracy Krumme +1 910 558 4186 investors@ppd.com
Pharmaceutical Product Developme (NASDAQ:PPDI)
Historical Stock Chart
From Jun 2024 to Jul 2024
Pharmaceutical Product Developme (NASDAQ:PPDI)
Historical Stock Chart
From Jul 2023 to Jul 2024